Navigation Links
Analysis Confirms Diabetes Drug May Harm the Heart
Date:3/18/2011

THURSDAY, March 17 (HealthDay News) -- A new analysis confirms that those who take the diabetes drug Avandia are more likely to develop heart problems and die than those who take a similar type of diabetes medication.

"The effect on public health may be considerable," the analysis authors wrote.

Avandia (rosiglitazone) helps control blood sugar levels in the body, and is prescribed for patients with type 2 diabetes. Studies in recent years have differed about whether it boosts the risk of heart disease and death.

In response to growing concerns over the drug's cardiovascular effects, U.S. health officials in September restricted the use of Avandia to patients with type 2 diabetes who cannot control their disease on other medications.

In the new analysis, researchers looked at the results of 16 studies that involved 810,000 users of Avandia or Actos (pioglitazone), a similar diabetes medication. The findings appear online March 17 in the BMJ.

The researchers found a "modest but statistically significant increase" in the odds of certain heart conditions in those who took Avandia. The risk of heart attack rose by 16 percent and increased 23 percent for congestive heart failure. Overall, mortality rates rose 14 percent.

Avandia is a common drug, with about 3.8 million prescriptions a year in the United States.

The analysis authors cautioned that Actos carries its own risks. Like Avandia, it's been linked to a doubling of risk of fracture in women. And researchers worry that it may slightly boost the risk of bladder cancer.

"Patients should review this study with their physician to gain a better understanding of how their personal circumstances may or may not be reflected in the study, and talk to their physicians about the risks versus the benefit of taking the drug," said Dr. Debra Wertz, outcomes research manager for HealthCore Inc., the research subsidiary of the insurance company WellPoint.

Wertz co-authored a 2010 study that found no significant differences in risk of heart attack, heart failure or death in patients who took the two drugs.

"One thing to consider is that the HealthCore study evaluated a population that is commercially insured and potentially younger [most were under 65] and healthier" than the studies analyzed in the meta-analysis, Wertz noted.

More information

For more about diabetes, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Debra Wertz, Pharm.D., outcomes research manager, HealthCore Inc., Wilmington, Del.; March 17, 2011, BMJ


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Analysis Confirms Avandia May Harm the Heart
2. mygenomatix: A secure cloud-like model for next-gen sequencing data analysis
3. Tissue Analysis May Help Predict Breast Cancer Outcome
4. Peer Support Beats Usual Care for Depression, Analysis Finds
5. Competing risks analysis highlights new targets in preventing ESRD and death of diabetics
6. Zinc May Help Ease Common Cold: Analysis
7. Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say
8. Gay Teens Punished More Harshly Than Straight Peers: Analysis
9. Obesity Can Shorten Life, Analysis Finds
10. Pharmacists Improve Patient-Care Teams: Analysis
11. Mammals Grew Big After Dinosaurs Died Off: Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Analysis Confirms Diabetes Drug May Harm the Heart
(Date:3/29/2017)... ... March 29, 2017 , ... ... for documenting and diagramming network and data center assets and audio-video devices has ... can request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... ... 29, 2017 , ... Hamlin Dental Group, multi-location dental office in North ... Dental lasers are safe and effective options, and can be used alone or in ... overall quality of care. , Dr. Hamid Reza of Hamlin Dental Group offers other ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education Resource® (PER®), ... medical education conference for clinicians who manage some of the most difficult-to-treat forms ... , The program will be led by co- chairs Dr. John Marshall, chief ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: